In vitro evolution and whole genome analysis to study chemotherapy drug resistance in haploid human cells

Background In vitro evolution and whole genome analysis has proven to be a powerful method for studying the mechanism of action of small molecules in many haploid microbes but has generally not been applied to human cell lines in part because their diploid state complicates the identification of variants that confer drug resistance. To determine if haploid human cell could be used in MOA studies, we evolved resistance to five different anticancer drugs (doxorubicin, gemcitabine, etoposide, topotecan, and paclitaxel) using a near-haploid cell line (HAP1) and then analyzed the genomes of the drug resistant clones, developing a bioinformatic pipeline that involved filtering for high frequency alleles predicted to change protein sequence, or alleles which appeared in the same gene for multiple independent selections with the same compound. Applying the filter to sequences from 28 drug resistant clones identified a set of 21 genes which was strongly enriched for known resistance genes or known drug targets (TOP1, TOP2A, DCK, WDR33, SLCO3A1). In addition, some lines carried structural variants that encompassed additional known resistance genes (ABCB1, WWOX and RRM1). Gene expression knockdown and knockout experiments of 10 validation targets showed a high degree of specificity and accuracy in our calls and demonstrates that the same drug resistance mechanisms found in diverse clinical samples can be evolved, discovered and studied in an isogenic background.

[1]  Michael D. Urbaniak,et al.  Author Correction: Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis , 2023, Nature.

[2]  Jacob D. Durrant,et al.  Defining the Yeast Resistome through in vitro Evolution and Whole Genome Sequencing , 2021, bioRxiv.

[3]  P. Bednarski,et al.  The Effect of Glutathione Peroxidase-1 Knockout on Anticancer Drug Sensitivities and Reactive Oxygen Species in Haploid HAP-1 Cells , 2020, Antioxidants.

[4]  C. Furusawa,et al.  High-throughput laboratory evolution reveals evolutionary constraints in Escherichia coli , 2020, Nature Communications.

[5]  Jeffrey E. Barrick,et al.  Genomic evolution of antibiotic resistance is contingent on genetic background following a long-term experiment with Escherichia coli , 2020, Proceedings of the National Academy of Sciences.

[6]  R. Müller,et al.  Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma , 2020, Leukemia.

[7]  E. Winzeler,et al.  In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model , 2019, Science Translational Medicine.

[8]  Liping Jiang,et al.  Pyrroloquinoline quinine ameliorates doxorubicin-induced autophagy-dependent apoptosis via lysosomal-mitochondrial axis in vascular endothelial cells. , 2019, Toxicology.

[9]  A. Isaacs,et al.  Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model , 2019, BMC Cancer.

[10]  L. Steinmetz,et al.  Biological plasticity rescues target activity in CRISPR knock outs , 2019, Nature Methods.

[11]  Zhenqiang Fang,et al.  RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy , 2019, BMC urology.

[12]  R. Watters,et al.  Combination Therapy with Disulfiram, Copper, and Doxorubicin for Osteosarcoma: In Vitro Support for a Novel Drug Repurposing Strategy , 2019, Sarcoma.

[13]  Christina D Drenberg,et al.  A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML , 2019, Nature Communications.

[14]  V. Cooper,et al.  Biofilm-dependent evolutionary pathways to antibiotic resistance , 2019, bioRxiv.

[15]  M. Altmeyer,et al.  Efficient Pre-mRNA Cleavage Prevents Replication-Stress-Associated Genome Instability , 2019, Molecular cell.

[16]  D. Katsaros,et al.  TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers , 2019, Journal of Ovarian Research.

[17]  W. Fan,et al.  The role and mechanisms of action of microRNAs in cancer drug resistance , 2019, Clinical Epigenetics.

[18]  Manuel Llinás,et al.  Open-source discovery of chemical leads for next-generation chemoprotective antimalarials , 2018, Science.

[19]  E. Winzeler,et al.  Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome , 2018, Journal of medicinal chemistry.

[20]  Yongfei Hu,et al.  In vivo evolution of drug-resistant Mycobacterium tuberculosis in patients during long-term treatment , 2018, BMC Genomics.

[21]  J. Flowers,et al.  Origins and geographic diversification of African rice (Oryza glaberrima) , 2018, bioRxiv.

[22]  Joseph D. Janizek,et al.  Accurate classification of BRCA1 variants with saturation genome editing , 2018, Nature.

[23]  A. O. John.  Faculty Opinions recommendation of Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. , 2018 .

[24]  T. Ochiya,et al.  Emerging roles of long non‐coding RNA in cancer , 2018, Cancer science.

[25]  D. Sabatini,et al.  Histidine catabolism is a major determinant of methotrexate sensitivity , 2018, Nature.

[26]  T. Brummelkamp,et al.  Haploid genetic screens identify genetic vulnerabilities to microtubule‐targeting agents , 2018, Molecular oncology.

[27]  E. Winzeler,et al.  Using in Vitro Evolution and Whole Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery , 2018, ACS infectious diseases.

[28]  Youngjoo Kwon,et al.  Hyperactivated m-calpain affects acquisition of doxorubicin resistance in breast cancer cells. , 2018, Biochimica et biophysica acta. General subjects.

[29]  I. Gladhaug,et al.  Pancreatic Cancer Chemoresistance to Gemcitabine , 2017, Cancers.

[30]  Behzad Baradaran,et al.  The Different Mechanisms of Cancer Drug Resistance: A Brief Review , 2017, Advanced pharmaceutical bulletin.

[31]  A. Paige,et al.  WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response , 2017, Cell Death and Disease.

[32]  Nicholas J Monteleone,et al.  An evaluation of copy number variation detection tools for cancer using whole exome sequencing data , 2017, BMC Bioinformatics.

[33]  R. Lenski,et al.  Experimental evolution and the dynamics of adaptation and genome evolution in microbial populations , 2017, The ISME Journal.

[34]  Rommie E. Amaro,et al.  Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast. , 2017, ACS chemical biology.

[35]  M. Stratton,et al.  Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations , 2017, bioRxiv.

[36]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[37]  Victoria C. Corey,et al.  UDP-galactose and Acetyl-CoA transporters as Plasmodium multidrug resistance genes , 2016, Nature Microbiology.

[38]  S. Grant,et al.  Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors , 2016, Journal of Hematology & Oncology.

[39]  Glen Spraggon,et al.  Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness , 2016, Nature.

[40]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[41]  P. Chakravarty,et al.  ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells , 2016, British Journal of Cancer.

[42]  J. Taipale,et al.  The role of enhancers in cancer , 2016, Nature Reviews Cancer.

[43]  Gregory M. Goldgof,et al.  A broad analysis of resistance development in the malaria parasite , 2016, Nature Communications.

[44]  F. Supek,et al.  Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease , 2015, PLoS pathogens.

[45]  Xianquan Zhang,et al.  RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients–a short report , 2015, Cellular Oncology.

[46]  A. Lockhart,et al.  Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy , 2015, The AAPS Journal.

[47]  Ryuji Ikeda,et al.  Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. , 2015, Journal of pharmacological sciences.

[48]  John R Yates,et al.  CPSF30 and Wdr33 directly bind to AAUAAA in mammalian mRNA 3′ processing , 2014, Genes & development.

[49]  Russ B. Altman,et al.  PharmGKB summary: gemcitabine pathway , 2014, Pharmacogenetics and genomics.

[50]  F. Huang,et al.  A Small Molecule Inhibitor of Human RAD51 Potentiates Breast Cancer Cell Killing by Therapeutic Agents in Mouse Xenografts , 2014, PloS one.

[51]  M. Jaramillo,et al.  Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer , 2014, Angiogenesis.

[52]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[53]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[54]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[55]  M. Hayashi,et al.  DNA damage associated with mitosis and cytokinesis failure , 2013, Oncogene.

[56]  G. Casari,et al.  A reversible gene trap collection empowers haploid genetics in human cells , 2013, Nature Methods.

[57]  H. Carter,et al.  Identifying Mendelian disease genes with the Variant Effect Scoring Tool , 2013, BMC Genomics.

[58]  Tingjun Hou,et al.  Molecular Principle of Topotecan Resistance by Topoisomerase I Mutations through Molecular Modeling Approaches , 2013, J. Chem. Inf. Model..

[59]  B. Schmidt,et al.  The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. , 2012, Journal of molecular biology.

[60]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[61]  John A. Tallarico,et al.  Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite Cladosporin , 2012, Cell host & microbe.

[62]  M. Ishida,et al.  DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. , 2012, Biochemical and biophysical research communications.

[63]  Tatiana Popova,et al.  Supplementary Methods , 2012, Acta Neuropsychiatrica.

[64]  J. Dye,et al.  Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 , 2011, Nature.

[65]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[66]  Yves Pommier,et al.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. , 2010, Chemistry & biology.

[67]  L. Ellis,et al.  Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology , 2009, Clinical Cancer Research.

[68]  R. Aqeilan,et al.  WWOX: Its genomics, partners, and functions , 2009, Journal of cellular biochemistry.

[69]  Kenoki Ohuchida,et al.  Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. , 2008, Anticancer research.

[70]  W. Richard McCombie,et al.  Topoisomerase levels determine chemotherapy response in vitro and in vivo , 2008, Proceedings of the National Academy of Sciences.

[71]  A. Calcagno,et al.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. , 2008, Current molecular pharmacology.

[72]  Vincent Hernandez,et al.  An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site , 2007, Science.

[73]  G. Bepler,et al.  RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  E. Mini,et al.  Cellular pharmacology of gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[76]  E. Rubin,et al.  Mechanisms of resistance to topoisomerase I-targeting drugs , 2003, Oncogene.

[77]  T. Helleday,et al.  The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer , 2003, International journal of cancer.

[78]  MA Katharina Schwarze BSc,et al.  Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature , 2018, Genetics in Medicine.

[79]  M. Bjornsti,et al.  YeastSaccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin , 2004, Cancer Chemotherapy and Pharmacology.

[80]  R. Kurzrock,et al.  KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. , 1995, Leukemia.

[81]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .